Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446899 | Completed Phase 3 Results DMC FDA Drug

• 1 other identifier: D3461C00004
• Study Type: interventional
• Target: 373
• Locations: 15 countries
• Sites: 113

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Conditions

Active Systemic Lupus Erythematosus

Keywords

Active Systemic Lupus Erythematosus

Outcome Measures

Primary Outcomes (1)

• Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52

  Composite endpoint BICLA was defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

  Baseline; Week 52

Secondary Outcomes (9)

• Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group

  Baseline; Week 52

• Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day

  Week 40; Week 52

• Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10

  Baseline; Week 12

• Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline

  Baseline; Week 52

• Annualised Flare Rate Through 52 Weeks

  Baseline to Week 52

Study Arms (2)

Anifrolumab

EXPERIMENTAL

Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.

Biological: Anifrolumab

Placebo

PLACEBO COMPARATOR

Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.

Drug: Placebo

Interventions

Anifrolumab BIOLOGICAL

Intravenous infusion (IV)

Anifrolumab

Placebo DRUG

Intravenous infusion (IV)

Placebo

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 through 70 years at the time of screening
• Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria ≥24 weeks prior to signing the Informed Consent form (ICF)
• Currently receiving at least 1 of the following:
• Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent and through Day 1:
• (i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day
• Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:
• Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre ≥1:80; OR
• Anti-dsDNA antibodies at screening elevated to above normal (including indeterminate), as per the central laboratory; OR
• Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory
• At Screening, Disease Activity Adjudication Group confirmation of:
• Must not have active or latent TB on either chest radiograph or by quantiferon gold test
• Day 1 "Clinical" SLEDAI-2K score ≥4 points
• OCS dose stable for at least 2 weeks prior to randomisation
• Stable SLE SOC treatment at the time of randomisation
• Women of child-bearing potential must have a negative serum β-hCG test at and negative urine pregnancy test at randomisation prior to administration of investigational product

You may not qualify if:

• Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater
• Receipt of any of the following:
• (a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1
• History of, or current diagnosis of, a clinically significant non SLE-related vasculitis syndrome.
• Active severe or unstable neuropsychiatric SLE
• Active severe SLE-driven renal disease
• Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.
• History of, or current, inflammatory joint or skin disease other than SLE
• History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the ICF
• Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation
• Confirmed positive test for hepatitis B or hepatitis C
• Any severe herpes infection at any time prior to Week 0 (Day 1)
• Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization
• History of cancer, apart from:
• Squamous or basal cell carcinoma of the skin that has been successfully treated

Sponsors & Collaborators

• AstraZeneca: lead
• PRA Health Sciences: collaborator

Study Sites (113)

Research Site

Covina, California, 91723, United States

Location

Research Site

Hemet, California, 92543-4403, United States

Location

Research Site

Los Angeles, California, 90095, United States

Location

Research Site

San Leandro, California, 94578, United States

Location

Research Site

Torrance, California, 90509, United States

Location

Research Site

Upland, California, 91786, United States

Location

Research Site

Denver, Colorado, 80230, United States

Location

Research Site

Bridgeport, Connecticut, 06606, United States

Location

Research Site

Bridgeport, Connecticut, 6606, United States

Location

Research Site

Brandon, Florida, 33511, United States

Location

Research Site

Orlando, Florida, 32804, United States

Location

Research Site

Palm Harbor, Florida, 34684, United States

Location

Research Site

Tamarac, Florida, 33321, United States

Location

Research Site

Tampa, Florida, 33614, United States

Location

Research Site

Atlanta, Georgia, 30303, United States

Location

Research Site

Boston, Massachusetts, 02118, United States

Location

Research Site

Ann Arbor, Michigan, 48109, United States

Location

Research Site

Lincoln, Nebraska, 68516, United States

Location

Research Site

Las Cruces, New Mexico, 88011, United States

Location

Research Site

Brooklyn, New York, 11201, United States

Location

Research Site

New York, New York, 10016, United States

Location

Research Site

New York, New York, 10021, United States

Location

Research Site

New York, New York, 10032, United States

Location

Research Site

Greenville, North Carolina, 27834, United States

Location

Research Site

Oklahoma City, Oklahoma, 73104, United States

Location

Research Site

Duncansville, Pennsylvania, 16635, United States

Location

Research Site

Pittsburgh, Pennsylvania, 15213, United States

Location

Research Site

Memphis, Tennessee, 38163, United States

Location

Research Site

Dallas, Texas, 75231, United States

Location

Research Site

Houston, Texas, 77004, United States

Location

Research Site

Houston, Texas, 77034, United States

Location

Research Site

Stafford, Texas, 77477, United States

Location

Research Site

Arlington, Virginia, 22205, United States

Location

Research Site

Seattle, Washington, 98122, United States

Location

Research Site

Spokane, Washington, 99204, United States

Location

Research Site

Buenos Aires, C1015ABO, Argentina

Location

Research Site

Mendoza, 5500, Argentina

Location

Research Site

Quilmes, 1878, Argentina

Location

Research Site

Brussels, 1070, Belgium

Location

Research Site

Leuven, 3000, Belgium

Location

Research Site

Liège, B-4000, Belgium

Location

Research Site

Merksem, B-2170, Belgium

Location

Research Site

Goiânia, 74110-120, Brazil

Location

Research Site

Juiz de Fora, 36010 570, Brazil

Location

Research Site

São Paulo, 04032-060, Brazil

Location

Research Site

São Paulo, 05403-9000, Brazil

Location

Research Site

São Paulo, 05652-900, Brazil

Location

Research Site

Plovdiv, 4002, Bulgaria

Location

Research Site

Plovdiv, 4003, Bulgaria

Location

Research Site

Hamilton, Ontario, L8S 4K1, Canada

Location

Research Site

Rimouski, Quebec, G5L 5T1, Canada

Location

Research Site

Bordeaux, 33000, France

Location

Research Site

Lille, 59037, France

Location

Research Site

Montpellier, 34295, France

Location

Research Site

Paris, 75651, France

Location

Research Site

Paris, 75679, France

Location

Research Site

Pessac, 33604, France

Location

Research Site

Toulouse, 31000, France

Location

Research Site

Berlin, D-10117, Germany

Location

Research Site

Hamburg, 20246, Germany

Location

Research Site

Jena, 07747, Germany

Location

Research Site

Mainz, 55131, Germany

Location

Research Site

München, 80336, Germany

Location

Research Site

Chiba, 260-8712, Japan

Location

Research Site

Chūōku, 104-8560, Japan

Location

Research Site

Fukuoka, 810-8539, Japan

Location

Research Site

Fukuoka, 810-8563, Japan

Location

Research Site

Hiroshima, 730-8619, Japan

Location

Research Site

Kitakyushu-shi, 807-8555, Japan

Location

Research Site

Kurashiki-shi, 710-8522, Japan

Location

Research Site

Meguro-ku, 152-8902, Japan

Location

Research Site

Meguro-ku, 153-8515, Japan

Location

Research Site

Nagasaki, 852-8501, Japan

Location

Research Site

Nagoya, 460-0001, Japan

Location

Research Site

Omura-shi, 856-8562, Japan

Location

Research Site

Sapporo, 060-8638, Japan

Location

Research Site

Sasebo-shi, 857-1195, Japan

Location

Research Site

Sendai, 980-8574, Japan

Location

Research Site

Shinjuku-ku, 160-8582, Japan

Location

Research Site

Tsukuba, 305-8577, Japan

Location

Research Site

Kaunas, LT-50009, Lithuania

Location

Research Site

Klaipėda, LT-92288, Lithuania

Location

Research Site

Chihuahua City, 31000, Mexico

Location

Research Site

León, 37000, Mexico

Location

Research Site

Mexico City, 014080, Mexico

Location

Research Site

Mérida, 97000, Mexico

Location

Research Site

México, 06700, Mexico

Location

Research Site

Morelia, 58070, Mexico

Location

Research Site

San Luis Potosí City, 78213, Mexico

Location

Research Site

Kemerovo, 650066, Russia

Location

Research Site

Petrozavodsk, 185019, Russia

Location

Research Site

Smolensk, 214015, Russia

Location

Research Site

Tolyatti, 445039, Russia

Location

Research Site

Vladimir, 600023, Russia

Location

Research Site

Yaroslavl, 150003, Russia

Location

Research Site

Cape Town, 7500, South Africa

Location

Research Site

Johannesburg, 2188, South Africa

Location

Research Site

Johannesburg, 2193, South Africa

Location

Research Site

Stellenbosch, 7600, South Africa

Location

Research Site

Jeju City, 690-767, South Korea

Location

Research Site

Seoul, 05030, South Korea

Location

Research Site

Seoul, 06591, South Korea

Location

Research Site

Seoul, 133792, South Korea

Location

Research Site

Suwon, 16499, South Korea

Location

Research Site

Barcelona, 08035, Spain

Location

Research Site

Getafe, 28905, Spain

Location

Research Site

Las Palmas de Gran Canaria, 35010, Spain

Location

Research Site

Madrid, 28046, Spain

Location

Research Site

Madrid, 28702, Spain

Location

Research Site

Mérida, 06800, Spain

Location

Research Site

Santiago de Compostela, 15706, Spain

Location

Research Site

Servilla, 41014, Spain

Location

Research Site

Vigo, 36200, Spain

Location

Related Publications (10)

• Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023 May;82(5):639-645. doi: 10.1136/ard-2022-222748. Epub 2023 Jan 23.

  PMID: 36690388 DERIVED

• Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). 2023 Apr 3;62(4):1526-1534. doi: 10.1093/rheumatology/keac491.

  PMID: 36018235 DERIVED

• Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 Jul;81(7):962-969. doi: 10.1136/annrheumdis-2021-221847. Epub 2022 May 17.

  PMID: 35580976 DERIVED

• Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25.

  PMID: 35338035 DERIVED

• Loncharich MF, Anderson CW. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14.

  PMID: 35157371 DERIVED

• Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022 May 5;61(5):1900-1910. doi: 10.1093/rheumatology/keab704.

  PMID: 34528084 DERIVED

• Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul;30(8):1254-1263. doi: 10.1177/09612033211014267. Epub 2021 May 12.

  PMID: 33977796 DERIVED

• Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis Rheumatol. 2021 Nov;73(11):2059-2068. doi: 10.1002/art.41778. Epub 2021 Sep 22.

  PMID: 33913260 DERIVED

• Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.

  PMID: 33687069 DERIVED

• Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.

  PMID: 31851795 DERIVED

Related Links

• Redacted CSP
• Redacted SAP

MeSH Terms

Interventions

anifrolumab

Results Point of Contact

• Title: Global Clinical Lead
• Organization: AstraZeneca AB

ClinicalTrialTransparency@astrazeneca.com

+46317761000

Study Officials

• Lilia Pineda, MD

  Medical Science Director

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2015
• First Posted: May 18, 2015
• Study Start: July 9, 2015
• Primary Completion: September 27, 2018
• Study Completion: September 27, 2018
• Last Updated: January 10, 2023
• Results First Posted: March 18, 2020

Record last verified: 2022-12

Locations

AR (3); ME (7); BE (4); US (35); JP (17); KR (5); ES (9); CA (2); LI (2); DE (5); BR (5); ZA (4); RU (6); FR (7); BU (2)